Glioblastoma multiforme: evidence-based approach to therapy (Q37030797)

17 August 2017

1 reference

title

Glioblastoma multiforme: evidence-based approach to therapy (English)

1 reference

17 August 2017

1 reference

M Kelly Nicholas

1

1 reference

17 August 2017

1 December 2007

1 reference

Expert Review of Anticancer Therapy

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

12 Suppl

1 reference

17 August 2017

S23-7

1 reference

Altered molecular pathways in gliomas: an overview of clinically relevant issues

17 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Surgical management of high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Role of radiotherapy in the treatment of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: a surrogate marker of brain penetration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

From triazines and triazenes to temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.12S.S23

10.1586/14737140.7.12S.S23

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18076314